The Health Ministry is advising of the voluntary recall of one lot of Heparin Sodium in 0.9% Sodium Chloride Injection to the consumer level.

The recall was issued by Baxter International Inc. due to the potential for elevated endotoxin levels based on issues related to the bacterial endotoxin test specific to lot number N008235.

Heparin Sodium in Sodium Chloride Injection is indicated as an anticoagulant to maintain catheter patency and is packaged in 2,000 USP units, 1,000 mL in VIAFLEX Plus Plastic Container -1 unit per pouch.

Use of heparin with higher than acceptable endotoxin levels may lead to significant adverse health consequences ranging from febrile reactions to toxic shock, multi-organ failure and death.

According to the recall, this issue affects one lot of product code that was distributed between March 12th 2023 and August 24th 2023, to healthcare facilities, wholesalers and distributors in the United States.

The Ministry says while the recalled products are not registered for use in T&T, persons who may be in possession are urged to discontinue use immediately and return to the place of purchase where possible.